NexThera’s Eye Drop Therapeutics &
Delivery Platform
Non-invasive delivery of therapeutic peptides through the extracellular matrix
reduces the risk and discomfort associated with intravitreal injections.
Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR)
AMD and DR are some of the leading causes of blindness in patients aged 40 years and older.
Age-Related Macular Degeneration
Diabetic Retinopathy
Wet AMD and proliferative DR are characterized by abnormal retinal neovascularization. The current standard of care is intravitreal injection of anti-vascular epithelial growth factor (anti-VEGF). While effective, this is an invasive treatment method that causes patient discomfort and can lead to side effects including infection, bleeding, and retinal detachment. NexThera is developing a non-invasive, peptide-based eye drop therapy for wet AMD (NT-101) and DR (NT-102) as a safer and more convenient solution for patients.
Intravitreal injection
Eye drop therapy
NexThera’s eye drop therapy delivers PEDF, a peptide that inhibits angiogenesis, into the retina.
The efficacy of NT-101 was demonstrated to be equivalent or greater than that of EYLEA (an approved treatment for wet AMD that is administered via intravitreal injection) in rodent animal models.
Preventive effect
Therapeutic effect
Protein Polymer Platform Nanostructures &
Biobetter Platform
Nanopolymers formed through NexThera's protein polymer platform can be leveraged as biobetters for various pharmaceutical products and drug delivery platforms.
Technology Applicability
Biobetter Development Technology
Functional Peptide Nanostructures
Antibody Fragment Nanostructures
Protein Nanostructures
Drug-Loaded Nanostructures
Intellectual Property
Introducing the Latest Information on NexThera’s Intellectual Property
Patent number
Patent filing date
2017. 06. 08
Registration number
Registration date
2018. 10. 02